| Name | Recombinant Human PCSK9 (D374Y,C-6His) |
| Purity | Greater than 95% as determined by reducing SDS-PAGE |
| Endotoxin level | <1 EU/µg as determined by LAL test. |
| Construction | Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln692 (Asp374Tyr,Val474Ile, Gly504Arg, Gly670Glu) is expressed with a 6His tag at the C-terminus. |
| Accession # | Q8NBP7 |
| Host | Human Cells |
| Species | Human |
| Predicted Molecular Mass | 15-18&60-80 KDa |
| Buffer | Supplied as a 0.2 μm filtered solution of 50mM HEPES, 150mM NaCl, 20% Glycerol, pH 7.4. |
| Form | Liquid |
| Shipping | The product is shipped on dry ice/polar packs.Upon receipt, store it immediately at the temperature listed below. |
| Stability&Storage | Store at ≤-70°C, stable for 6 months after receipt.Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles. |
Alternative Names
Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1; NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; PCSK9; NARC1
Background
Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9/PCSK9 (D374Y) is a gain of function mutant of human PCSK9 protein. Human PCSK9 is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain are secreted together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and it plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.
Note
For Research Use Only , Not for Diagnostic Use.